• 1
    Hochberg MC, Lopez-Acuna D, Gittelsohn AM. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum 1983; 26: 146571.
  • 2
    Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol 1990; 17: 132934.
  • 3
    Kurland LT, Hauser WA, Ferguson RH, Holley KE. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969; 44: 64963.
  • 4
    Medsger TA Jr, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48: 71523.
  • 5
    Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies [review]. Rheum Dis Clin Am 2002; 28: 891916.
  • 6
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 36074.
  • 7
    Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198204.
  • 8
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 5419.
  • 9
    Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis [review]. N Engl J Med 1991; 325: 148798.
  • 10
    Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 34356.
  • 11
    Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 70421.
  • 12
    Engel A, Hohlfield R, Banker B. The polymyositis and dermatomyositis syndromes. In: EngelA, ArmstrongC, editors. Myology. New York: McGraw-Hill; 1994. p. 133583.
  • 13
    Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122: 71524.
  • 14
    Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990: diagnosis, treatment and prognosis. Prog Neurobiol 1990; 35: 18193.
  • 15
    Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980; 92: 3659.
  • 16
    Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981; 24: 458.
  • 17
    Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72: 22535.
  • 18
    Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 3929.
  • 19
    Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 11439.
  • 20
    Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29: 95102.
  • 21
    Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 12258.
  • 22
    Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 3741.
  • 23
    Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Ziza JM, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis [letter]. Lancet 1990; 336: 116.
  • 24
    Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 1628.
  • 25
    Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 10927.
  • 26
    Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 46774.
  • 27
    Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 19932000.
  • 28
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 7126.
  • 29
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 3237.
  • 30
    Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998; 65: 10710.
  • 31
    Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247: 228.
  • 32
    Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999; 52: 17014.
  • 33
    Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 4859.
  • 34
    Levine TD. B cell depletion chemotherapy in the treatment of dermatomyositis. 23rd Annual Carrell-Krusen Symposium, Dallas, TX. March 2001.
  • 35
    Bohan A, Peter JB. Polymyositis and dermatomyositis [review]. N Engl J Med 1975; 292: 3447.
  • 36
    Pestronk A, Lopate G, Kornberg AJ, Elliott JL, Blume G, Yee WC, et al. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1994; 44: 202731.
  • 37
    Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 142433.
  • 38
    Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 7117.
  • 39
    Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C. J Biol Chem 1989; 264: 112827.
  • 40
    Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135: 9739.
  • 41
    Tedder TF, Zhou LJ, Bell PD, Frizzell R, Bubien J. The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 1990; 140: 195.
  • 42
    McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26(5 Suppl 14 ): 7987.
  • 43
    Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders [review]. Biochem Soc Trans 2002; 30: 8248.
  • 44
    Albert DA, Khan SR, Stansberry J, Tsai D, Eisenberg RA. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum 2003; 48: 3659.
  • 45
    Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience [review]. Ann Rheum Dis 2003; 62 Suppl: ii55–9.
  • 46
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 257281.
  • 47
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 25809.
  • 48
    Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]. Drugs 2003; 63: 80343.